Opgenra (eptotermin alfa)
- Region
- 🇪🇺 EU
- Active substance
- eptotermin alfa
- Company
- Olympus Biotech International Limited
- Status
- Withdrawn
- Therapeutic area
- Spondylolisthesis
- EU approval
- Thu 19 Feb 2009
- Application
- EMEA/H/C/000819
- ATC
- M05BC02
- Official record
- www.ema.europa.eu
Indication
Opgenra is indicated for posterolateral lumbar spinal fusion in adult patients with spondylolisthesis where autograft has failed or is contra-indicated.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Osigraft Withdrawn · Olympus Biotech International Limited
Follow Opgenra
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.